First Patients Implanted with Axonics® Sacral Neuromodulation System in U.S. FDA Pivotal Study
Axonics Modulation Technologies, Inc., developer of the first rechargeable sacral neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, today announced that the first 11 patients of the ARTISAN-SNM study have been implanted in four centers located in the United States and Western Europe.
ARTISAN-SNM is a single-arm, prospective pivotal study designed to demonstrate the safety and effectiveness of the Axonics r-SNM system as an aid in the treatment of urinary urge incontinence in patients who have failed or could not tolerate more conservative treatments. Axonics expects to implant approximately 120 patients at 15 centers of excellence located in the U.S. and Western Europe.
The ARTISAN-SNM clinical study is being conducted under an Investigational Device Exemption (IDE) granted by the U.S. Food & Drug Administration (FDA), and is designed to gain FDA Premarket Approval in the United States.
“Our clinical study is off to a fast start, led by investigators eager to use our product,” said Raymond W. Cohen, Chief Executive Officer of Axonics. “Given the number of centers who wished to participate in the study and worldwide patient demand for SNM therapy, we expect to complete enrollment in record time.”
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is a privately-held venture backed company that has developed a novel implantable neuromodulation technology for patients with urinary and bowel dysfunction and can be further directed towards other clinical indications. The Axonics r-SNM system includes a miniaturized rechargeable implantable stimulator qualified to function at least 15 years, a charging system optimized for reduced charge time without overheating, a patient-friendly remote control and an intuitive clinician programmer that facilitates the lead placement procedure and programming.
During 2016, the Axonics r-SNM system gained regulatory approval in Europe and Canada for the treatment of overactive bladder, urinary retention, and fecal incontinence.
For more information, visit the Company’s website at www.axonicsmodulation.com .
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
Chief Operating & Financial Officer
Investor & Media Contact
Matt Clawson, +1-949-370-8500
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
WA-AMAZON.COM19.4.2018 15:02 | pressemeddelelse
Amazon Studios Greenlights Utopia, Signs Gillian Flynn to Overall Deal
DELTICOM-AG19.4.2018 14:49 | pressemeddelelse
Yourtyres.co.uk at The Tire Cologne 2018: Concepts for Linking Online and Offline Business
FLOWSION19.4.2018 13:50 | pressemeddelelse
Flowsion A/S Wins Horizon 2020 SME Instrument Grant for Automatic Glucose Control in Intensive Care Medicine
NEXPERIA19.4.2018 11:35 | pressemeddelelse
Nexperia Secures $800M Financing to Fund Future Growth Plans
GRUNDIG19.4.2018 11:21 | pressemeddelelse
Grundig – Redefining Kitchen Design and Technology
PIXID19.4.2018 11:11 | pressemeddelelse
PIXID Continues European Expansion with Acquisition of Dutch Staffing CRM Supplier Carerix
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum